Your browser is no longer supported. Please, upgrade your browser.
CLSD Clearside Biomedical, Inc. monthly Stock Chart
Clearside Biomedical, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own7.60% Shs Outstand46.98M Perf Week10.17%
Market Cap93.78M Forward P/E- EPS next Y-0.41 Insider Trans14.08% Shs Float44.51M Perf Month41.30%
Income-14.20M PEG- EPS next Q-0.12 Inst Own41.40% Short Float3.25% Perf Quarter13.37%
Sales9.80M P/S9.57 EPS this Y70.10% Inst Trans1.04% Short Ratio8.58 Perf Half Y5.41%
Book/sh0.17 P/B11.47 EPS next Y-13.90% ROA-65.30% Target Price- Perf Year35.42%
Cash/sh- P/C- EPS next 5Y- ROE-153.40% 52W Range1.10 - 4.13 Perf YTD-32.76%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-185.90% 52W High-52.78% Beta1.21
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low77.27% ATR0.13
Employees33 Current Ratio2.00 Sales Q/Q2334.00% Oper. Margin- RSI (14)70.92 Volatility9.50% 8.81%
OptionableYes Debt/Eq0.12 EPS Q/Q69.60% Profit Margin- Rel Volume2.16 Prev Close1.96
ShortableYes LT Debt/Eq0.05 EarningsNov 10 AMC Payout- Avg Volume168.39K Price1.95
Recom2.10 SMA2024.84% SMA5027.62% SMA2006.38% Volume363,472 Change-0.51%
May-13-20Initiated ROTH Capital Buy $8
Aug-09-19Downgrade Needham Buy → Hold
Nov-05-18Downgrade Stifel Buy → Hold
Nov-05-18Downgrade JP Morgan Overweight → Underweight
Nov-05-18Downgrade Cowen Outperform → Market Perform
Mar-06-18Reiterated Needham Buy $18 → $22
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
Nov-27-20 04:53PM  
Nov-16-20 07:05AM  
Nov-11-20 07:05AM  
Nov-10-20 04:05PM  
Oct-30-20 07:05AM  
Oct-27-20 05:24AM  
Sep-23-20 07:05AM  
Sep-11-20 08:30AM  
Sep-09-20 04:05PM  
Sep-02-20 08:37AM  
Aug-26-20 07:05AM  
Aug-10-20 06:45PM  
Aug-04-20 07:05AM  
Aug-03-20 12:31PM  
Jul-30-20 07:05AM  
Jul-29-20 12:33PM  
Jul-27-20 07:05AM  
Jun-22-20 12:00PM  
Jun-17-20 07:05AM  
Jun-04-20 06:23PM  
May-08-20 08:45AM  
May-06-20 12:30PM  
Apr-28-20 07:05AM  
Apr-22-20 07:05AM  
Apr-09-20 07:05AM  
Apr-08-20 07:05AM  
Mar-30-20 08:15PM  
Mar-11-20 05:45PM  
Mar-04-20 12:30PM  
Feb-27-20 07:05AM  
Feb-26-20 07:05AM  
Feb-25-20 07:05AM  
Feb-05-20 07:05AM  
Jan-28-20 07:36AM  
Jan-20-20 06:28AM  
Jan-06-20 07:05AM  
Dec-31-19 07:09AM  
Dec-24-19 12:15PM  
Dec-18-19 09:10AM  
Nov-29-19 10:29AM  
Nov-22-19 05:19PM  
Nov-13-19 04:05PM  
Nov-06-19 07:05PM  
Oct-30-19 04:05PM  
Oct-23-19 07:54AM  
Oct-17-19 04:05PM  
Oct-13-19 04:33PM  
Oct-03-19 07:05AM  
Sep-19-19 07:05AM  
Sep-17-19 06:27AM  
Sep-09-19 09:38PM  
Sep-04-19 07:00AM  
Sep-03-19 04:05PM  
Aug-28-19 10:34AM  
Aug-22-19 07:05AM  
Aug-07-19 08:25PM  
Aug-06-19 04:35PM  
Jul-31-19 04:30PM  
Jul-18-19 07:05AM  
Jul-09-19 07:05AM  
Jun-19-19 06:50AM  
Jun-11-19 07:05AM  
May-15-19 09:16PM  
May-08-19 07:05AM  
May-01-19 07:05AM  
Apr-25-19 07:05AM  
Apr-18-19 07:05AM  
Apr-08-19 07:05AM  
Apr-02-19 04:05PM  
Mar-18-19 09:38PM  
Mar-12-19 04:05PM  
Mar-04-19 07:05AM  
Feb-27-19 07:05AM  
Feb-25-19 01:27PM  
Feb-20-19 01:20PM  
Feb-19-19 07:05AM  
Feb-15-19 10:00AM  
Jan-20-19 11:15AM  
Jan-02-19 08:00AM  
Dec-21-18 09:43AM  
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WHITMORE BRADFORD T10% OwnerNov 24Buy1.6562,000102,0463,074,000Nov 24 04:46 PM
WHITMORE BRADFORD T10% OwnerNov 16Buy1.6962,000104,9293,012,000Nov 16 04:36 PM
LASEZKAY GEORGE MCEOSep 22Sale1.5913,41121,323302,689Sep 24 04:42 PM
Humphries William D.DirectorAug 18Buy1.785,5869,9435,586Aug 18 07:53 PM
WHITMORE BRADFORD T10% OwnerAug 13Buy1.6550,00082,5602,950,000Aug 13 04:01 PM
WHITMORE BRADFORD T10% OwnerAug 12Buy1.63300,000489,1202,900,000Aug 13 04:01 PM
Deignan Charles A.Chief Financial OfficerJun 01Sale1.8814,99228,185220,827Jun 03 04:43 PM
Hutson Nancy JDirectorMay 20Buy1.855,0009,2505,000May 21 04:50 PM
LASEZKAY GEORGE MCEOMay 12Sale1.9932,15063,979311,100May 13 04:15 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.